Innovative Diagnostic Platform Telo Genomics has developed a proprietary telomere analysis platform with applications in oncology and neurological diseases, providing opportunities to offer advanced digital diagnostic solutions to hospitals, research institutions, and biotech partners focusing on personalized medicine.

Clinical Validation and Publications With over 150 peer-reviewed studies and involvement in clinical trials with more than 3,000 patients, Telo Genomics demonstrates strong clinical validation, making it an attractive partner for medical device companies and diagnostic labs seeking reliable prognostic tools.

Growing Market Presence Active participation in international conferences such as EHA, ASCO, and the International Myeloma Society indicates a growing visibility within key oncology and hematology communities, facilitating potential sales leads with leading healthcare providers and research entities.

Funding and Expansion Recent oversubscribed financing of 2.5 million dollars underscores investor confidence, supporting the company's plans for product development, market expansion, and strategic partnerships in the rapidly evolving liquid biopsy and precision medicine sectors.

Leveraging Technology and Data Using advanced AI, molecular biology, and cloud infrastructure, Telo Genomics is positioned to deliver scalable, high-accuracy diagnostic products, creating opportunities to partner with biotech firms, pharmaceutical companies, and healthcare providers seeking innovative disease monitoring solutions.